Epstein-Barr virus and multiple sclerosis: Evidence of association from a prospective study with long-term follow-up

Archives of Neurology

Volumn 63, Issue 6, 2006, Pages 839-844

  DeLorenze, Gerald N ^a   Munger, Kassandra L ^b   Lennette, Evelyn T ^d   Orentreich, Norman ^e   Vogelman, Joseph H ^e   Ascherio, Alberto ^b,c,f  

^a DIVISION OF RESEARCH   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Virolab Inc   (United States)

^e Orentreich Foundation for the Advancement of Science Inc   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIBODY; EPSTEIN BARR VIRUS ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; UNITED STATES;

ADULT; ANTIBODIES, VIRAL; CASE-CONTROL STUDIES; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW-UP STUDIES; HERPESVIRUS 4, HUMAN; HUMANS; MALE; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 33745107637     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.63.6.noc50328     Document Type: Article

References (29)

1. Gale CR, Martyn CN. Migrant studies in multiple sclerosis. Prog Neurobiol. 1995;47:425-448.
2. Ascherio A, Munch M. Epstein-Barr virus and multiple sclerosis. Epidemiology. 2000;11:220-224.
3. Alotaibi S, Kennedy J, Tellier R, et al. Epstein-Barr virus in pediatric multiple sclerosis. JAMA. 2004;291:1875-1879.
4. Ascherio A, Munger KL, Lennette ET, et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA. 2001;286:3083-3088.
5. Levin LI, Munger KL, Rubertone MV, et al. Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA. 2005;293:2496-2500.
6. DeStefano F, Verstraeten T, Jackson LA, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol. 2003;60:504-509.
7. Poser CM. Onset symptoms of multiple sclerosis. J Neurol Neurosurg Psychiatry. 1995;58:253-254.
8. Henle W, Henle G, Andersson J, et al. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc Natl Acad Sci U S A. 1987;84:570-574.
9. Lennette ET, Rymo L, Yadav M, et al. Disease-related differences in antibody patterns against EBV-encoded nuclear antigens EBNA 1, EBNA 2 and EBNA 6. Eur J Cancer. 1993;29A:1584-1589.
10. Lennette ET, Lennette D. Immune adherence hemagglutination. In: Specter S, Hodinka R, Young S, eds. Clinical Virology Manual. Washington, DC: ASM Press; 2000:140-145.
11. Diggle P, Liang K, Zeger S. Analysis of Longitudinal Data. Oxford, England: Clarendon Press; 1994.
12. Breslow NE, Day NE. The analysis of case-control studies. In: Davis W, ed. Statistical Methods in Cancer Research. Vol 1. Lyon, France: IARC Scientific Publications; 1980:1-338.
13. Sundstrom P, Juto P, Wadell G, et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology. 2004;62:2277-2282.
14. Kusunoki Y, Huang H, Fukuda Y, et al. A positive correlation between the precursor frequency of cytotoxic lymphocytes to autologous Epstein-Barr virus-transformed B cells and antibody titer level against Epstein-Barr virus-associated nuclear antigen in healthy seropositive individuals. Microbiol Immunol. 1993;37:461-469.
15. Kurtzke JF. Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev. 1993;6:382-427.
16. Welsh RM, Selin LK. No one is naive: the significance of heterologous T-cell immunity. Nat Rev Immunol. 2002;2:417-426.
17. Kieff E. Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. Philadelphia, Pa: Lippincott-Raven Publishers; 1996:2343-2396.
18. Yao QY, Rowe M, Martin B, et al. The Epstein-Barr virus carrier state: dominance of a single growth- transforming isolate in the blood and in the oropharynx of healthy virus carriers. J Gen Virol. 1991;72:1579-1590.
19. Gratama JW, Ernberg I. Molecular epidemiology of Epstein-Barr virus infection. Adv Cancer Res. 1995;67:197-255.
20. Munch M, Hvas J, Christensen T, et al. A single subtype of Epstein-Barr virus in members of multiple sclerosis clusters. Acta Neurol Scand. 1998;98:395-399.
21. Sitki-Green D, Covington M, Raab-Traub N. Compartmentalization and transmission of multiple Epstein-Barr virus strains in asymptomatic carriers. J Virol. 2003;77:1840-1847.
22. Holmoy T, Vartdal F. Cerebrospinal fluid T cells from multiple sclerosis patients recognize autologous Epstein-Barr virus-transformed B cells. J Neurovirol. 2004;10:52-56.
23. Lang HL, Jacobsen H, Ikemizu S, et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol. 2002;3:940-943.
24. Hollsberg P, Hansen HJ, Haahr S. Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis. Clin Exp Immunol. 2003;132:137-143.
25. Rand KH, Houck H, Denslow ND, et al. Epstein-Barr virus nuclear antigen-1 (EBNA-1) associated oligoclonal bands in patients with multiple sclerosis. J Neurol Sci. 2000;173:32-39.
26. Pender MP. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol. 2003;24:584-588.
27. van Sechel AC, Bajramovic JJ, van Stipdonk MJ, et al. EBV-induced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis. J Immunol. 1999;162:129-135.
28. Cepok S, Zhou D, Srivastava R, et al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest. 2005;115:1352-1360.
29. James JA, Neas BR, Moser KL, et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum. 2001;44:1122-1126.